Skip to main content
Contact Us
Subscribe
E-Edition
41°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Marinus Pharmaceuticals
< Previous
1
2
3
Next >
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
March 27, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 21, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 16, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
November 20, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 14, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV
November 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
September 19, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
September 12, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
August 17, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 11, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder
July 31, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
July 27, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 13, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus
June 21, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 02, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
May 26, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
May 17, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.